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Objectives The aim of this study was to evaluate the relative frequency of access and nonaccess
site bleeding, the association of these events with 1-year mortality, and the impact of randomized
antithrombotic therapy.
Background Post-percutaneous coronary intervention (PCI) bleeding has been strongly associated
with subsequent mortality. The extent to which access versus nonaccess site bleeding contributes to
this poor prognosis and the role of antithrombotic therapies remains poorly understood.
Methods The incidence and impact of Thrombolysis In Myocardial Infarction (TIMI) major/minor 30-day
bleeding and randomized antithrombotic therapy were examined in a combined dataset from the
REPLACE-2 (Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events), Acute Catheter-
ization and Urgent Intervention Triage Strategy (ACUITY), and HORIZONS-AMI (Harmonizing Outcomes
with Revascularization and Stents in Acute Myocardial Infarction) trials in 17,393 PCI patients.
Results The TIMI major/minor bleeding occurred in 5.3% of patients, 61.4% of which (3.3%) were
nonaccess site bleeds. After multivariable adjustment, TIMI bleeding was associated with an in-
creased risk of 1-year mortality (hazard ratio [HR]: 3.17, 95% conﬁdence interval [CI]: 2.51 to 4.00,
p  0.0001). The HR of a nonaccess site bleed was approximately 2-fold that of an access site bleed:
HR: 3.94, 95% CI: 3.07 to 5.15, p  0.0001 versus HR: 1.82, 95% CI: 1.17 to 2.83, p  0.008, respec-
tively. Randomization to bivalirudin versus heparin  a glycoprotein IIb/IIIa inhibitor resulted in 38%
and 43% relative reductions in TIMI major/minor and TIMI major bleeding, respectively (p  0.0001
for both), with signiﬁcant reductions in both access and nonaccess site bleeding.
Conclusions Nonaccess site bleeding after PCI is common, representing approximately two-thirds of
all TIMI bleeding events, and is associated with a 4-fold increase in 1-year mortality. Use of bivaliru-
din rather than heparin  a glycoprotein IIb/IIIa inhibitor signiﬁcantly decreases both nonaccess site
as well as access site bleeding events by approximately 40%. (J Am Coll Cardiol Intv 2011;4:191–7)
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192The most common in-hospital complications of percutane-
ous coronary intervention (PCI) are myocardial infarction
(MI) and bleeding (1–4). Both of these adverse events are
independently and strongly associated with long-term mor-
tality, with comparable prognostic impact (1,2). The con-
sistent association between these modifiable complications
and survival highlights the importance of selecting pharma-
cological therapies and interventional techniques that min-
imize both.
A frequent source of bleeding for PCI patients is the arterial
access site, in particular femoral artery access. Although radial
artery access has been associated with a significant reduction in
overall bleeding (3), most patients enrolled in trials examining
the outcomes of antithrombotic agents have undergone PCI
with femoral artery access (4–9). In such patients bleeding
might arise from either the femoral access site or other sources.
The relative frequency and contribution of hemorrhagic com-
plications from femoral versus nonfemoral bleeding sites to
the long-term prognosis of patients after PCI has not been
determined.
In the current analysis the data
from 3 large-scale, prospective,
randomized trials of bivalirudin
versus heparin plus a glycoprotein
IIb/IIIa inhibitor (GPI) were
pooled to evaluate the relative in-
cidence of access site and nonac-
cess site bleeding, the association
of these events with 1-year mor-
tality, and the relative impact of
randomized antithrombotic ther-
apy on each type of bleeding.
These studies span the whole
spectrum of clinical settings for
PCI, ranging from patients undergoing elective PCI (in the
REPLACE-2 [Randomized Evaluation in PCI Linking An-
giomax to Reduced Clinical Events] trial) to non–ST-segment
elevation acute coronary syndromes (in the ACUITY [Acute
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Methods
The current study population consists of 17,393 patients
who underwent PCI as part of the REPLACE-2 (5),
ACUITY (6), and HORIZONS-AMI (7) trials. The de-
tails of the study designs, end points, definitions, and results
for each study have been previously described. A brief
summary of these trials follows.
The REPLACE-2 trial included 6,010 patients undergoing
elective or urgent PCI. Patients were randomized to heparin
(65 U/kg bolus) plus a GPI or bivalirudin (0.75 mg/kg bolus
before PCI with 1.75 mg/kg/h infusion during procedure) with
provisional GPI use. All patients received aspirin, whereas
pretreatment with clopidogrel with daily administration for at
least 30 days after intervention was strongly encouraged. A
PCI was performed only via the femoral approach. The
ACUITY trial enrolled 13,819 patients with moderate- to
high-risk acute coronary syndrome and in whom an invasive
approach was planned. Patients were randomized to either
heparin (unfractionated or enoxaparin) plus GPI, bivalirudin
with planned GPI, or bivalirudin with provisional GPI. Un-
fractionated heparin was administered as an intravenous bolus
of 60 U/kg followed by a 12 U/kg/h infusion to target an
activated partial thromboplastin time of 50 to 75 s before
angiography and an activated clotting time of 200 to 250 s
during PCI. Bivalirudin was administered as an intravenous
bolus of 0.1 mg/kg with an infusion of 0.5 mg/kg before PCI,
which was subsequently increased to 1.75 mg/kg/h during
PCI. Aspirin was administered daily during the hospital stay,
whereas clopidogrel use was left to the discretion of the
individual investigators, although a loading dose of 300 mg or
more was required in all patients no later than 2 h after PCI.
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193After angiography 7,789 patients underwent PCI. Only these
patients are included in the present analysis; choice of vascular
access site was left to the discretion of the investigator. The
HORIZONS-AMI trial enrolled 3,602 patients with STEMI
being treated with primary PCI. Patients were randomized to
either heparin (60 IU/kg bolus with subsequent boluses tar-
geting an activated clotting time of 200 to 250 s) with planned
GPI therapy or to a bivalirudin (0.75 mg/kg bolus and 1.75
mg/kg/h infusion) with provisional GPI therapy. Again, all
patients received aspirin and clopidogrel before and after PCI,
and choice of vascular access site was left to the investigator.
End points and deﬁnitions. This study focuses on bleeding
nd points measured at 30 days. The 30-day protocol-
efined bleeding differed among the 3 trials, with their
pecific definitions noted in their original reports. Throm-
olysis In Myocardial Infarction (TIMI) major and minor
leeding was assessed in all 3 trials, however. Therefore, the
ccurrence of TIMI major or minor bleeding was chosen as
he primary end point for the present study. The TIMI
ajor bleeding was defined as a reduction of hemoglobin of
5 g/dl (or 15% in hematocrit), with or without overt
leeding, or any intracranial bleeding. A TIMI minor
leeding was defined as a 3 to 5 g/dl decrease in hemoglobin
or 10% to 15% in hematocrit) with an observed source of
leeding or a hemoglobin drop of 4 to 5 g/dl (or 12% to 15%
ematocrit) without an observed source. A transfusion of a
nit of whole blood or packed red blood cells was factored
nto the evaluation of blood loss and considered the equiv-
lent of 1 g/dl of hemoglobin or 3% in hematocrit.
Bleeding location was determined locally by the investi-
ators and recorded on the case report form. For the present
nalysis, access site bleeding was defined a priori as any
leeding identified as arising only from the access or
uncture site or retroperitoneal in origin. Nonaccess site
leeding was defined as bleeding that was not confined to
he access site only. Nonaccess site bleeding was further
ubdivided into 3 mutually exclusive cohorts: patients with
oth an access site and nonaccess bleed, patients with a
onaccess site bleed only, and those patients in whom no
ource for bleeding was identified.
Statistical analysis. Continuous variables were summarized
y means and SD. Categorical variables were summarized
y frequencies and percentage. A p value of 0.05 was
onsidered statistically significant. Comparisons among
reatment groups were made with the normal approxima-
ion test for population proportions.
The rates of 1-year mortality as a function of access site
nd nonaccess site bleeding were determined. To evaluate
he adjusted association between bleeding site and 1-year
ortality, we constructed a Cox proportional hazards re-
ression model that adjusted for baseline characteristics.
ovariates were selected with a forward stepwise procedure
rom a large number of candidate variables with p  0.20 as
he criterion for entry into the model. The followingariables were included in the model: age as a continuous
ariable, anemia, baseline myocardial enzyme (creatine
inase-myocardial band or troponin) elevation, baseline
reatinine clearance 60 ml/min, current smoker, diabetes
ellitus, previous MI, and STEMI as presenting diagnosis.
ertinent candidate variables evaluated but not generally
elected included randomized therapy, race, hypertension,
ex, weight, previous PCI, multivessel intervention, and
aseline platelet count 100,000. Adjusted hazard ratios
HRs) of the risk for mortality with 95% confidence
ntervals (CIs) are presented. We performed, as a secondary
nalysis, an analysis to examine the effect of different
harmacological regimens on both access site and nonaccess
ite bleeding by constructing a model that examined the
ffect of the different pharmacological regimens. All statis-
ical analyses were performed by SAS (version 8.2, Cary,
orth Carolina).
esults
Of the 23,431 patients enrolled in the REPLACE-2,
ACUITY, and HORIZONS-AMI trials, 17,393 were
treated with PCI and were included in the present analysis.
Patient demographic data and treatment characteristics are
representative of the diverse patient populations enrolled in
the 3 trials (Table 1). A TIMI major/minor bleeding
occurred in 925 patients (5.3%), including TIMI major
bleeding in 279 (1.6%) and minor bleeding in 646 (3.7%)
patients. Overall TIMI bleeding rates were 2.9%, 6.9%, and
5.8% in the REPLACE-2, ACUITY, and HORIZONS-
AMI trials, respectively.
Sites of bleeding. Access site bleeding occurred in 2.1% of
all patients (1.1%, 2.9%, and 1.9% in the REPLACE-2,
ACUITY, and HORIZONS-AMI trials, respectively),
whereas the rate of nonaccess site bleeding was 3.3%
overall (1.8%, 4.1%, and 3.9% in the REPLACE-2,
ACUITY, and HORIZONS-AMI trials, respectively).
Among the 925 patients with a TIMI major/minor bleed,
access site-related bleeding occurred in 357 (38.6%), and
nonaccess site-related bleeding occurred in 568 (61.4%)
(Fig. 1). The median time (interquartile range) from enroll-
ment until a TIMI bleeding event was 1.0 (IQR: 0.0 to 1.0)
day for access site bleeding and 2.0 (IQR: 1.0 to 2.0) days
for nonaccess site-related bleeding.
The origin and classification of the site of bleeding among
the 925 patients with a TIMI bleeding event is shown in
Figure 1. Among the 568 patients with a nonaccess TIMI
bleed, a total of 621 bleeding sites were documented with the
breakdown of locations shown in Figure 2. The incidence of
access site bleeding was as in the following text.
Association between bleeding etiology and 1-year mortality.
Compared with patients without TIMI major/minor bleed-
ing within 30 days, the unadjusted relative risk of 1-year
mortality among patients in whom any TIMI major/minor
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194bleeding occurred was 4.22 (95% CI: 3.44 to 5.19), p 
0.001. Unadjusted mortality rates and relative risks by
bleeding location are shown in Table 2.
After adjustment for baseline and procedural character-
istics, TIMI major/minor bleeding still remained signifi-
cantly associated with 1-year mortality (HR: 3.17, 95% CI:
2.51 to 4.00), p  0.0001). The adjusted mortality risk
associated with an access site-only bleed compared with no
bleeding (HR: 1.82, 95% CI: 1.17 to 2.83, p  0.008) was
significant but lower than that associated with nonaccess site
bleeding (HR: 3.94, 95% CI: 3.07 to 5.15, p  0.0001).
When the adjusted 1-year mortality risk of a nonaccess site
bleed was compared with that of an access site bleed, the
hazard associated with a nonaccess site bleed was signifi-
cantly greater than that of an access site bleed (HR: 2.27,
95% CI: 1.42 to 3.64, p  0.0007). Similar to the unad-
justed data, the source of nonaccess bleeding did not alter
Table 1. Patient Demographic Data and Procedural Characteristics
(n  17,393)
Demographic data
Age (yrs) 62.3 11.4
Age 75 yrs 16.0%
Weight (kg) 85.6 17.8
Female 25.7%
Diabetes 25.1%
Current smoker 32.3%
Creatinine clearance 60 ml/min 17.0%
Hypertension (on medication) 63.5%
Anemia 8.9%
Prior PCI 31.6%
Prior CABG 14.8%
Presenting diagnosis
STEMI 20.7%
NSTEMI 30.0%
Unstable angina 29.5%
Stable angina 8.6%
Other 11.2%
Procedural characteristics
Balloon/atherectomy only 6.5%
Stent
Bare-metal only 50.9%
Any drug-eluting 58.2%
Multivessel intervention 12.6%
Femoral artery access site* 92.9%
Radial artery access site* 7.1%
Baseline medications
Aspirin pre-angiography 98.0%
Thienopyridine pre-angiography 80.0%
Statins 49.9%
Values aremean SD or%. *Access site in the REPLACE-2 (Randomized Evaluation in PCI Linking
Angiomax toReducedClinical Events) trialwasnot documentedbut assumed tobe100% femoral
for this analysis.
CABG coronary artery bypass graft surgery; NSTEMI non–ST-segment elevation myocar-
dial infarction; PCI percutaneous coronary intervention; STEMI ST-segment elevation myo-cardial infarction.the risk: 1-year mortality was strongly associated with
nonaccess only bleeding (HR: 2.78, 95% CI: 1.62 to 4.78, p
 0.0002); combined access and nonaccess bleeding (HR:
3.64, 95% CI: 2.25 to 5.90, p  0.0001); and indeterminate
bleeding location (HR: 4.72, 95% CI: 3.38 to 6.59, p 
0.0001).
Inﬂuence of randomized therapy. To determine the impact
of antithrombotic therapy on the incidence of access and
nonaccess site-related bleeding, 14,784 patients who had
been randomized to either bivalirudin alone or heparin plus
a GPI were evaluated. Randomization to bivalirudin re-
sulted in a 38% relative reduction in TIMI major/minor
bleeding (Fig. 3) and a 43% reduction in TIMI major
bleeding. Bivalirudin decreased both access and nonaccess
site-related TIMI major/minor and TIMI major bleeding
events compared with treatment with heparin plus a GPI
Figure 1. Study Patient Categorization
Classiﬁcation of patients with a Thrombolysis In Myocardial Infarction (TIMI)
major or minor bleeding event. PCI  percutaneous coronary intervention.
Figure 2. Distribution of Locations of Nonaccess Site Bleeding EventsTIMI  Thrombolysis In Myocardial Infarction.
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195(Fig. 3). Similar levels of reduction in bleeding with
bivalirudin were found for all bleeding sites (Fig. 4). The
number needed-to-treat was 71 to prevent 1 nonaccess
site-related TIMI bleeding event, considering noncoronary
artery bypass graft surgery TIMI major/minor bleeding
only, and 74 to prevent 1 access site-related TIMI bleeding
event by use of bivalirudin rather than heparin plus a GPI.
Discussion
Bleeding, like peri-procedural MI, is a frequent complica-
tion of PCI and has been strongly associated with subse-
quent mortality (8,9). The present analysis is the largest to
date describing the anatomic origin of bleeding after PCI.
We found that, whereas access site-only bleeding was a
frequent source of bleeding in patients undergoing PCI,
most patients (61.4%) with TIMI major/minor bleeding
had a bleeding source other than the access site. Moreover,
although the present study confirmed bleeding as a powerful
independent predictor of long-term (1-year) mortality,
novel to this analysis is the finding that the degree of risk
Table 2. Unadjusted 1-Year Mortality Rates and RRs Associated With
Experiencing a 30-Day TIMI
1-Yr
Mortality
(%)
RR (95% CI)
Compared
With No Bleed p Value
No bleed 2.54 — —
Access site only 6.16 2.33 (1.53–3.53) 0.001
All nonaccess site 14.4 5.40 (4.32–6.74) 0.0001
Nonaccess only 14.1 5.52 (3.62–8.40) 0.001
Both access and nonaccess 14.5 5.70 (3.78–8.61) 0.001
Indeterminate 14.6 5.18 (3.82–7.03) 0.001
Unadjusted 1-year mortality rates and relative risks (RRs) associated with experiencing a 30-day
Thrombolysis In Myocardial Infarction (TIMI) (majorminor) bleed on the basis of the source of
bleeding.
CI confidence interval.
Figure 3. RR of Location-Specific TIMI Bleeding by Randomized Therapy
Inﬂuence of randomized therapy, bivalirudin alone versus heparin plus glycop
Myocardial Infarction (TIMI) major plus minor bleeding on the basis of the etiology oassociated with bleeding is dependent upon the bleeding
source: nonaccess site TIMI bleeding events were associated
with a nearly 4-fold increase in 1-year mortality compared
with patients without any bleeding event, representing an
approximate 2-fold increase in the mortality risk compared
with access site-only TIMI bleeds. These findings reinforce
the need to identify treatment strategies that diminish not
only access site bleeding but, even more importantly, non-
access site bleeding.
Arterial access via the radial artery might improve both
the safety and post-procedural comfort of patients under-
going PCI. Although the randomized trials required to
determine whether radial artery compared with femoral
artery access improves overall outcomes in PCI have not yet
been performed, numerous observational studies have
shown that the transradial approach might reduce the
incidence of access site-related hemorrhagic complications
(10). In the present study of more than 17,000 PCI, most
patients (61.4%) with TIMI major/minor bleeding had a
bleeding source other than the access site. Although radial
artery access (used in only 7.9% of patients) might reduce
most access site bleeds, it would not be expected to reduce
nonaccess site-related bleeding events, which not only
constitute a significant proportion of TIMI bleeds but are
also associated with an even greater risk of subsequent
1-year mortality than access site bleeds.
Certain antithrombotic agents in a variety of clinical
settings have been shown to be able to significantly reduce
bleeding while effectively suppressing ischemic complica-
tions (5–7,11,12). This overall improvement of net adverse
clinical events has been found to translate into improve-
ments in long-term outcomes, including survival (12,13).
Although bivalirudin compared with unfractionated heparin
alone (4) or heparin plus a GPI (5–7) has been shown to
significantly reduce overall major bleeding complications in
patients undergoing a PCI, its influence on reducing access
IIb/IIIa inhibitor (GPI), on the relative risk (RR) of 30-day Thrombolysis Inrotein
f the bleed. CI  conﬁdence interval.
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196and nonaccess site major bleeding has not been previously
reported. In the current analysis of nearly 15,000 PCI
patients randomized to either bivalirudin or heparin plus a
GPI, bivalirudin was equally effective in decreasing both
access and nonaccess site-related bleeding, with an approx-
imately 40% relative reduction in combined TIMI major/
minor bleeding and TIMI major bleeding alone. Although
the relative reduction in bleeding with bivalirudin is inde-
pendent of bleeding location, the absolute mortality benefit
of bivalirudin might be greatest from the prevention of
nonaccess site-related bleeds. In this regard, even if all
access bleeding were eliminated by the use of radial artery
access, the number needed-to-treat with bivalirudin to
prevent a single nonaccess site related TIMI major/minor
bleed that is associated with a 4-fold increase in mortality at
1-year is only 71 patients.
After access site bleeding, the genitourinary and gastro-
intestinal systems represented the most common specific
locations associated with TIMI bleeding events, perhaps not
unexpected due to comorbidities, stress ulcers among
acutely ill patients, and the use of bladder catheterization.
What might be less commonly appreciated is the relatively
high incidence of “indeterminate location” major bleeding
events, representing patients with substantial decreases in
hemoglobin (4 to 5 g/dl) and/or transfusions with no clear
source of bleeding. Such bleeding events represented 30% of
all TIMI bleeding in the present study and almost one-half
of all such events unrelated to the access site. The etiology
of such non-overt blood loss is unclear. Frequent or complex
exchanges of PCI equipment, dilution due to various
infusions, and frequent blood sampling are potential con-
tributors to peri-procedural blood loss, the magnitude of
Figure 4. Relative Risk of TIMI Bleeding in Different Organ Systems by Ran
Inﬂuence of randomized therapy, bivalirudin alone versus heparin plus GPI, on
of the location. GI  gastrointestinal; GU  genitourinary; HEENT  head, eyewhich is frequently underappreciated. Baseline anemia isassociated with an increased risk of in-hospital major
bleeding, death, and MI (14,15) and is also likely to lower
the clinical threshold for blood transfusions (16). In the
ABOARD (Acute Coronary Syndromes Randomized for
an Immediate or Delayed Intervention) trial in which 84%
of patients underwent early invasive management of acute
coronary syndrome via a radial approach, there was no
clinical evidence of a source of bleeding in 37% of patients
(17), consistent with our findings. Thus many or most of
these “indeterminate location” bleeding events are likely
nonaccess site-related in origin.
Study limitations. First, in patients who were found to have
oth access and nonaccess site bleeding events, it was not
ossible to determine the severity of each and therefore
hich location contributed more to the individual bleeding
vent. Second, as previously discussed, the bleeding site was
ndeterminate in 281 patients in the present study. How-
ver, even if all of these patients were excluded from the
nalysis, nonaccess site bleeding still accounted for 287 of
38 bleeds (45.0%), confirming the necessity to select
herapies that mitigate both access site and nonaccess site
leeding. Third, the associations noted between type, sever-
ty, and site of bleeding and subsequent mortality are
bservational and subject to potential confounding.
onclusions
On the basis of the present analysis of over 17,000 patients
undergoing PCI across the spectrum of coronary artery
disease (ranging from stable ischemic syndromes to STEMI),
almost two-thirds of patients with TIMI major or minor
bleeding will involve a source other than the arterial access
zed Therapy
elative risk of 30-day nonaccess TIMI major plus minor bleeding on the basis
, nose, and throat; other abbreviations as in Figure 3.domi
the rsite. Although all bleeding, irrespective of the source, is
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197independently associated with a significant increase in
mortality at 1 year, the risk associated with bleeding
originating from locations other than the access site were
found to be 2-fold the risk of an access site bleed and
4-fold the risk of no bleed. Bivalirudin compared with
heparin plus a GPI significantly reduces all TIMI bleeding
events to a comparable degree, regardless of the bleeding
location, and thus would be expected to improve patient
outcomes irrespective of the individual patient risk for access
site bleeding or use of transradial versus femoral access.
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